William O'Neill, MD, shares insights from the National Cardiogenic Shock Initiative (NCSI) Study that are driving improved outcomes in patients with AMI cardiogenic shock.
Duane Pinto, MD, MPH discusses the new single access technique, designed to avoid an additional arterial access, and reduce associated complications as well as make the procedure more rapid
Efforts to prevent thrombus formation among blood-contacting medical devices such as the Impella® heart pump include administration of anticoagulant medications such as heparin and direct thrombin inhibitors
TCT Connect highlighted the benefits of a more complete revascularization with Impella heart pumps in high-risk PCI patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients.
Vasileios Panoulas, MD, and colleagues assess the clinical utility, indications, and outcomes of the Impella platform in their tertiary center in London, UK.
Learn when and how to use echocardiography to visualize in real-time the relationship of the Impella 5.5 with SmartAssist to structures within the left ventricle.
Ameloot et al. report significant reduction in myocardial injury with target MAP between 80/85 and 100 mmHg in post-cardiac arrest patients with shock after AMI.
Prof. Andreas Schäfer, MD discusses standardized use of Impella in AMICS and predicted mortality rates, timing of implantation, and patient selection based on predicted risk.
Steven P. Keller, MD, examines different mechanical circulatory support strategies for left ventricular unloading in ECMO supported patients in cardiogenic shock.